```html

Herpes Simplex Virus Type 2 (HSV‑2) – A Comprehensive Medical Guide

Overview

Herpes simplex virus type 2 (HSV‑2) is a DNA virus that primarily causes genital herpes. It is a lifelong infection that resides in nerve cells and can reactivate periodically, producing recurrent sores. While both men and women can be infected, women experience higher rates of symptomatic disease and complications such as neonatal herpes.

• Global prevalence: The World Health Organization estimates that ≈ 417 million people worldwide are living with HSV‑2.
• United States: Approximately 12 % of people aged 14–49 have HSV‑2 antibodies (CDC, 2022).
• Age & gender: Prevalence rises with age, peaking in the 30‑40 year range. Women are about 1.5‑2 times more likely than men to be infected.

HSV‑2 is a sexually transmitted infection (STI). It can be spread through vaginal, anal, or oral sex and, less commonly, from a mother to her baby during delivery.

Symptoms

Many people with HSV‑2 never notice symptoms, but when they occur they usually appear within 2‑12 days after exposure.

Primary (first‑episode) infection

• Genital or anal sores: Small, fluid‑filled blisters that rupture to form painful ulcers.
• Systemic signs: Fever, headache, muscle aches, swollen lymph nodes, and malaise.
• Urinary discomfort: Burning during urination if sores are near the urethra.
• Vaginal discharge: In women, a watery or mucous discharge may accompany lesions.

Recurrent episodes

• Prodrome: Tingling, itching, or burning sensation 12‑24 hours before lesions appear.
• Localized sores: Typically fewer (1‑3) and smaller than primary lesions; last 5‑10 days.
• Asymptomatic shedding: Virus can be present on the skin without visible lesions, facilitating transmission.

Other possible manifestations

• Herpetic meningitis (rare) – headache, neck stiffness, fever.
• Herpetic whitlow – painful finger blisters after oral/genital exposure.
• Eye involvement (herpes keratitis) – usually HSV‑1 but can occur with HSV‑2 in rare cases.

Causes and Risk Factors

Cause

HSV‑2 is an enveloped double‑stranded DNA virus from the Herpesviridae family. After initial infection, the virus establishes latency in the sacral dorsal‑root ganglia (for genital infection) and can reactivate under certain triggers.

Risk factors

• Unprotected sexual contact: Vaginal, anal, or oral sex without condoms or dental dams.
• Multiple sexual partners: Increases exposure opportunities.
• History of other STIs: Particularly HIV, which impairs immune response.
• Female sex: Larger mucosal surface area in the genital tract facilitates viral entry.
• Pregnancy: Hormonal changes can reactivate latent virus.
>
• Immunosuppression: Transplant recipients, chemotherapy, or advanced HIV infection.
• Stress, illness, or hormonal fluctuations: Common triggers for reactivation.

Diagnosis

Because HSV‑2 can mimic other dermatologic conditions, laboratory confirmation is essential.

Specimen collection

1. Lesion swab (PCR or culture): The most accurate test if sores are present. A swab is taken from the base of an ulcer before it crusts.
2. Blood test (serology): Detects HSV‑2–specific IgG antibodies. Useful when lesions are absent or for epidemiologic screening.

Laboratory methods

• Polymerase chain reaction (PCR): Sensitivity > 95 % for active lesions; can differentiate HSV‑1 from HSV‑2.
• Viral culture: Less sensitive than PCR; often used when PCR is unavailable.
• Type‑specific serology (ELISA or Western blot): Helps identify past infection; may give false‑negative results in the first 6 weeks after exposure.

Clinical diagnosis

If a patient presents classic recurrent genital ulcers, a presumptive diagnosis may be made, but confirmatory testing is still recommended, especially before initiating suppressive therapy.

Treatment Options

There is currently no cure for HSV‑2; treatment focuses on reducing symptom severity, shortening outbreaks, and limiting transmission.

Antiviral medications

Drug	Typical dosage	Use
Acyclovir	400 mg PO 5×/day (episodic) or 400 mg PO BID (suppressive)	First‑line, inexpensive
Valacyclovir	1 g PO BID (episodic) or 500 mg PO daily (suppressive)	Better bioavailability, once/twice‑daily dosing
Famciclovir	250 mg PO TID (episodic) or 250 mg PO BID (suppressive)	Alternative for those who cannot tolerate acyclovir

Starting therapy within 72 hours of lesion onset yields the greatest benefit (Mayo Clinic, 2023).

Suppression therapy

• Daily antiviral reduces outbreak frequency by ~70 % and cuts asymptomatic viral shedding by 50‑80 %.
• Recommended for patients with:
  • Four or more outbreaks per year, or
  • Genital shedding that risks neonatal transmission, or
  • Significant psychosocial impact.

Adjunctive measures

• Pain control: Over‑the‑counter NSAIDs (ibuprofen) or topical lidocaine.
• Hygiene: Keep lesions clean, avoid tight clothing, and wash hands after touching sores.
• Psychological support: Counseling or support groups reduce anxiety and stigma.

Living with Herpes Simplex Virus Infection (HSV‑2)

Effective self‑management can keep outbreaks mild and lower transmission risk.

• Track triggers: Use a diary or smartphone app to note stress, illness, menstrual cycle, or sun exposure that precede outbreaks.
• Prompt treatment: Keep a short course of antiviral medication on hand and start at the first sign of prodrome.
• Safe sexual practices:
  • Use latex condoms or dental dams every time.
  • Avoid intercourse during an outbreak or prodrome.
  • Discuss HSV status openly with partners.
• Consider suppressive therapy: Especially if you have frequent recurrences or are planning pregnancy.
• Vaccination updates: No approved HSV vaccine yet, but several candidates are in clinical trials (NIH, 2022).
• General health: Balanced diet, regular exercise, adequate sleep, and stress‑reduction techniques (mindfulness, yoga) can lessen reactivation frequency.

Prevention

Because HSV‑2 is incurable, prevention focuses on limiting exposure and minimizing viral shedding.

1. Consistent condom use: Reduces, but does not eliminate, transmission (≈ 30‑50 % risk reduction).
2. Limit number of sexual partners: Fewer partners mean fewer opportunities for exposure.
3. Partner testing and disclosure: Encourage mutual STI screening before initiating a relationship.
4. Avoid sexual contact during outbreaks or prodrome: Viral load is highest during these periods.
5. Daily suppressive antiviral therapy: Consider for seropositive individuals with frequent shedding.
6. Pregnancy considerations:
   • If a woman is HSV‑2 positive, plan delivery with obstetric care; a Cesarean section is recommended if lesions are present at labor.
   • Intravenous acyclovir may be given near term to reduce neonatal infection risk.

Complications

Although many infections are mild, untreated HSV‑2 can lead to serious health problems.

• Neonatal herpes: Occurs in 1‑2 % of infants born to mothers with primary genital HSV‑2 infection near delivery; mortality can exceed 50 % without treatment (CDC, 2021).
• Increased HIV acquisition: Genital ulcers provide an entry point for HIV; HSV‑2 infection doubles the risk of HIV seroconversion.
• Psychosocial impact: Depression, anxiety, and relationship strain are common.
• Recurrent meningitis (Mollaret’s meningitis): Rare, characterized by periodic headaches and stiff neck.
• Urinary retention: Severe lesions near the urethra can impede urine flow.

When to Seek Emergency Care

References

• World Health Organization. Herpes simplex virus Fact Sheet. 2023.
• Centers for Disease Control and Prevention. Genital Herpes – CDC STD Surveillance. 2022.
• Mayo Clinic. Genital herpes: Diagnosis and treatment. Updated 2023.
• Cleveland Clinic. Herpes Simplex Virus (HSV) Overview. 2024.
• National Institutes of Health. HSV vaccine research updates. 2022.
• American College of Obstetricians and Gynecologists. Genital Herpes in Pregnancy. 2020.

```